SEC Tracker
Get the app

Macrogenics MGNX

MacroGenics announces MGC026 interim data

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. Presented at ESMO Congress in Madrid from Oct 23-27, 2026
  2. Interim data from Phase 1 study on MGC026 for advanced solid tumors

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Macrogenics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Inovio Pharmaceuticals INO public float $74M, Jun 30, 2025
  2. Volitionrx VNRX public float $73M, Jun 30, 2025
  3. Gyre Therapeutics GYRE public float $73M, Jun 30, 2025
  4. Oncolytics Biotech ONCY public float $72M, Jun 30, 2025
  5. Seres Therapeutics MCRB public float $72M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.